Chemokines and their receptors may be used as entry points to regulate DC-T cell crosstalk in RA and to identify new target molecules that regulate CCR4, CCR5, CCR6, and their ligands, which can be used as the basis for screening RA-protective drugs and providing new strategies for the treatment of RA. This evidence concerns the gene CCR5 and rheumatoid arthritis.